Connecting the World for a CauseWELCOME NOTE. Fo THE PRESIDENT Dear DCVMN members, partners and friends, Welcome to the 19th DCVMN Annual General Meeting at Kunming, China. Over the last nearly 2 decades, DCVMN has made great progress with increase in numbers of members, partners and collaborators, who have contributed to and benefitted from this, association. Over the years, we have helped our members improve their technical expertise through trainings, seminars, undertaken various initiatives to help the industry ‘community and other stakeholders, and have helped the industry come together with new ideas to solve common technical, strategic and programmatic challenges facing the industry, This would not have been possible without the collaborative spirit demonstrated by the members and other partners. We are thankful for the efforts from all the stakeholders. This year we have undertaken a number of new initiatives which we hope would lead to further value creation for our members. One of the initiatives is to further define the role of DCVMN and to come up with a strategic plan for the organization for the next 5 years. This was based on an understanding to shape the Network and its goals in line with the industry challenges of current times. We have just completed the first phase of this exercise, to formulate the strategic goals for DCVMN, and we intend to present the findings to the members during the AGM for further discussion and adoption. Ihope, once we have implemented some or all of the recommendations of this exercise, we will see an improved DCVMN playing a much more significant role on the global immunization stage innearfuture ‘Our members have played an important role in improving supply security to the developing world over the last 18 years. Each year, a number of our members reach important milestones thus further enabling our commitment towards providing quality vaccines to developing countries. However, even today, vaccine preventable diseases lead to significant number of deaths in children and in adults. Anumber of epidemics and pandemics causing diseases still don't have viable supply situation. There are a number of neglected diseases for which vaccines can be made, but aren't being made due to economic considerations. A number of diseases are not being addressed due to technological challenges which need further R&D. It's time all the stakeholders come together to find solutions to these herculean challenges. At the same time, i's important that we address the low hanging fruits as quickly as possible. | hope the AGM provides all of us the right platform to discuss these important issues and to come up with the right frameworks to approach them. | wish you all a productive and enjoyable time at the DCVMN AGM 2018 and a successful yearahead. Warm regards, A achime Rohe Mahima Datla ® DCVMN PresidentEXECUTIVE COMMITEE MEMBERS Dr Sonia R Paglvs!Member Organizations’ Geographical Presence Argentina Bangladesh Brazil Cuba Egypt India Indonesia IR of Iran Mexico Pakistan P.R. China, Boll (HUME “@* Republic of Korea Russia, Saudi Arabia South Africa Taiwan Thailand Vietnam A, DEVELOPING COUNTRIES VACCINE MANUFACTURERS NETWORK devmn DeonName of the company : Amson Vaccine & Pharma (Pvt. Lid Head of insiitulion _: Mr. Shamim Ahmed Khan AMSON VACCINES & | sicblshed 1995 AMSON PHARMA (PVT) LTD. Location Pakistan Overview of the company Amson Vaccines & Pharma [Pvt] Lid, {sone of the leading pharmaceutical companies of Pakistan with the distinction of being the only one in the private sector that is Icensed lo manufacture vaccines. In addition lo vaccines, we also manufacture votious pharmaceuticals that are available throughout Pakistan through our distribution network, We are regular supplier of ‘our products to Government Programs and Institutes including Federal EP. We provide jobs fo above 950 personnel who are involved from production to selling / marketing of our prodvets, Vaccine being our especalily our interes! in vaccine delivery + system is quite natural We have set up a plant for the manufacturing of Auto Disable Syringesin Pakistan and four of our designs have been approved by World Health (Organization forsale to UNICEF and other UN Agencies, UNICEF has entered into a long term arrangements with us for the supply of our Auto Disable Syringe for he year 2018-2019 Our aim is to make Pakistan self sufficient in vaccine production and are in discussion with Government of Pakistan, for this purpose. Current Product Pipeline. ————________________________@ Product Name Description Type Presentation. ‘Vio/Ampoule 0.5/1.0/5.0/ 10.0 mi Imatet Injection, Tetanus Toxoid Vaccine [Vial / Ampoule: O.5mni7 Smt 7 TOE Amvax Injection Recombinant Hepatits | vial y Ampoule 0.5mi/1mi/Smi/10m1 BVaccine Polysaccharide Typhoid y jection mpoul {ypbor Injection vas Ampoule 0.5 mi ‘Anil Snae Venom Polyvatent Anti Snake Venom Serum [Serum (Liquid) (Indo — Vial 1omi Pak Sub Continent)Future Product Pipe Line_§ ———_____________________@ © Penlavalent Vaccine © AntiTetanus Serum © Seasonal Influenza Vaccine © Oral Cholera Vaccine The material will be imported in buk ready fo fl or concentrate form and filed at our facility Product Name Pre Clinical Phase? Clinical Phate2 Expected launch date Prose Quarter / Year oA Areas of Interest for Collaboration © J.V.for vaccine manufacturing © Typhoid conjugal vaccine {filing} © BCG vaccine [import and manufacturing) © MMR vaccine (Import and manufacturing) © Export of Auto Disable Syringes Contact Details Name of contact person Address city Stale Location Postal code Naveed Ahmed Khan © 115, Industrial Tangle, Kahuta Road Islamabad Pakistan 44000 DEVELOPING COUNTRIES VACCINE MANUFACTURERS Phone Mobile Fox emo Website NETWORK +492 (51) 4492022, +492 299.5567062 492,61) a4nr4ne noveedomson.org.pk www.amson.org.pk www.applysyringe.comName of the company : Arab Company for Pharmaceutical Products (Arabio). , Arabio Hood of ration :0x Abdutabman Amul (Arabia C£0) sab Conny Perri ett Established Arabio Is a limited liability company established in 2005. Country Saudi Arabia Overview of the company Arabio Is @ blophamaceutical company specialized in human vaccines, and other biopharmaceuticalsit Is the first biopharmaceutical companyin the Gulf Cooperation Council (GCC), The size and scope of activities intended to be yy NG made in Arabio would make Arabio the fist beers ti] biologicalcompany ofilskindin theregion. LUI ‘Araio aims to bring to the markets of the Middle East, North Africa, and high quality products that comply with the international quality standards ‘Arabio has production lines of pre-tiled syringes, liquid vials and lyophilized vials from the best global machines suppliers to make high quality products and meet CGMP & intemationalstandards Description of ARABIO capabilities Biological sterle manufacturing + PFS and vial ling. + PFS and vial bster packaging, Arabio Partners: + GSK Vaccines + InterVox Vaccine + BloFarme, Indonesia AbbVie.+ 18 Current Product Pipeline ___$_$_________ Product Name Description Type Presentation Viai/Ampoule 05/1.0/50/ 100m Hepat 8 Pediatric Vial Hopaiits 8 Adult Vial Measles Vial Meningococcal conjugate ACWY vaccine Vial Penta Vaccine (DIwP, Him, Hep 8) Vial Seasonal Influenza Vaccine PFS BCG ‘Amp! Tuberculn Vial ‘Oral Polo Vaccine [trvalent 10 ds Vial Tetanus Toxoid (TT) Vaccine 10 ds Viel Diphtheria Tetanus (DT) Pediatric Vaccine, VialFuture Product Pipe Line_§ ———_____________________@ Product Name Pre Clinical Clinical Phase? Phase 2 Expected launch date Prose Quarter / Year oA Areas of Interest for Collaboration eo 00000 Contact Details Name of contact person Adgress city Stale DEVELOPING COUNTRIES VACCINE Vaccines: Biological Products: Hepatilis A vaccine. © Immunology: - Rheumatold arthritis (RA) + Inflammatory bowel disease (IBD) Rota virus vaccine. MMR IMMRV vaccines. Pneumococcal vaccine, - Psoriasis and dermatologic diseases - Psoriatic arthritis (PSA) - Osteoarthritis (OA) + Systemic lupus erythematosus © Oncology: - Solid tumors Varicella vaccine. Dengue Fever vaccine - Hematologic malignancies - Next-generation immuno-oncology © Neuroscience: - Alzheimer's disease = Multiple sclerosis Parkinson's disease Hepatology Insulin Blood coagulation Growth hormones eo 0000 Erythropoietin Abdurahman Almutaiti (CEO and General Manager) Phone Mobile Tarek Ibrahim (Business Development & Strategic Alliance and Marketing Manager). Fax Corporate Office: Khurals Road, Khurais ‘Commercial center Opposite to King Fahad Medical City. P.O Box 63243, Riyadh11516, KSA, email Website Factory: Al Umrah District, Makkah Industrial Tone, P.O. Box 20355, Makkah 21955, KSA. Riyadh Central Province (Riyadh Region) Saudi Arabia sie MANUFACTURERS NETWORK +966 11.4615535, +966 565933303, +9661 4633729 farekibrahiméarabio.com www.arable.comName of he compony : Beijing Minhai Biotechnology Co.,Ltd. Mi N H A | Head of Insitution _: Mr. Zheng Haifa, General Manager Established 2004 Country PRChina. Overview of the company Beljng Minhal Biotechnology Co..L1d. [referred to as "Minha’"] is « modem biotechnology enterprise specialized in vaccine R&D, production and distribution, Minhals mission is lo provide safe, stable and affordable vaccines: increase immunization coverage, reduce the incidence of infectious disease and mortality: protect human health, Minhal was founded in June 2004, with a registered capital of 500 milion RMB and a total asset of 900 milion RMB, at No.35 Simiao Road, Bioengineering &Pharmaceutical Industrial Park, Daxing Dislrct, Beiing, which has « leading R&D center and a moder vaccine manufacturing site composed of over 60,000 m2 GMP compliant workshops, equipped with advanced lotge-scale bacteria vaccine production line and vius vaccine production ine. Until 2018, there are three commercialized vaccine producisin China, including Hib conjugate vaccine, MR vaccine and DTaP-Hib vaccine. DIaP-Hib vaccine, which is independently developed by Minhai. is the fist domestic tetravalent vaccine, There are over 20 vaccines in Minha!’ pipeline ([rom pre-clinical trial fo NDA, including pneumococcal conjugate vaccine, HDCV rabies vaccine, sabin PV and meningitis conjugale vaccine ele, In the meantime of developing novel vaccines, Minhai initialed intemational registration and accelerated the process of export. From 2013, Minhai has started the registration of three marketed producls in more than 15 countries including Uzbekistan, Pakistan, India, Russia and the Philippines, and initicted WHO. prequalification preparation. Minha is enlarging mult-angle, mult-level Intemational collaboration, and extensively promote globalization strategy. Minhai is collaborating and competing with world class vaccine enterprises, working hard to share Minhai’s safe, stable and affordable vaccines with all human beings round the world. Current Product Pipeline, ————_____________ lg Product Name Description. Type Presentation Vial Ampoule 05/1.0/50/100 mi ib Hemophils Influenae type b vaccine Vial ‘osm Diptheria, Tetanus, aecellular Pertussis, and DTaP-Hi Hemophilus Influenae type b combined vaccine Viel 0.5m140.5m1 aR ‘Measles and Rubella combined vaccine Vial Tyophived Heps Hepaiilis B vaccine Vial Toug.200g.600gFuture Product Pipe Line_§ ————_____________________@ Product Name Pre Clinical Phase 1 Clinical Phase 2 Expected launch date Phase 3 Quarter / Year 2awvalant Preumacoccal Polysaccharide Vaccine NDA ‘AGYWiasMaringococcal Polysaccharide Va NDA DieP NDA Hib fe) NDA DEV Rabiesleal factory) NDA Te-valent Preumocaccal Conjugate Vaccine Thacivared Hepa ‘ACYWI35 Meningococcal Sabin PY Varicella Seasonalinfivenza DEV rabies (Bioreactor) (CholeralOral TCP ib tho hi) Bier Fie ND DTcP-Hio-sIPV rolent POY Mumps ‘S-valen Relovinus MMR HEV Group 8 Ms ils “4 valent HFMD 19 Hep Blnasol spray TET © Technology Transfer © Vaccine Co-development © Overseas Registration and Distribution Contact Details Areas of Interest for Collaboration Name of contact per Adaress city Stale ostal code: DEVELOPING COUNTRIES Thang Qian Phone No.35 S| Miao Road Bioengineering Mobile ‘Pharmaceutical Industrial Park,Doxing Fax District, Beijing 102600 P.R.China email Belling Website PR. China 102600 VACCINE MANUFACTURERS NETWORK +86 10 59613590 +86 18618287689 +86 10 59613655 zhanggian@vip.126.com hitp://www.biominhai.com dcvmnName of the company : Bharat Biotech International Limited ® Bharat Head of halluion + De. tishna M. Ea Biotech Established 1996 rodl Srrorabion, County India Overview of the company Bharat Biotech was founded in 1996 by Dr. Krishna Fila and Mrs, Suchitra Ella, with focus on developing and manufacturing novel vaccines and biologics. The company has fully integrated expertise in Research & Development, Product Development, Clinical Development, GMP Manufacturing, Quality Management Systems, Marketing, Sales and Distribution, Bharat Biotech is a WHO Prequalified manufacturer of BIOPOLIO® (183); ROTAVAC® and Typbar TCV® for supply to UN Agencies, Bharal biotech has invested significantly into R&D which has resulled in development of breaklhrough vaccines such as Eco-friendly r Hepatitis 8 vaccine (cesium chloride and Thimerosal free]. Rotavirus vaccine from a naturally reassorted ‘and altenuatedstrain and world's fist clinically proven Typhoid Conjugate vaccine. ROTAVACBhos been includediinto the UIP program of Government of nga in 2016 and is being supplied to several States of India in a phased manner. These innovative vaccines reaffirm our focus on product development for developing world counties. Bharat Biotech has alonghistory of developing novelheallh care solutions with focus on developing world populations, Vaccinecandidates against Zika and CChikungunyainfections are now ready for Phase human clinical tia. Bharat Biotech has fled more than 250 paten!s worldwide and was granted ‘over 100 patents with a strong tradition of developing and respecting IPR With globally accredited faciliies, Bharat Biotech supoliesits products to more than 100 countries, Current Product Pipeline, ———______ lg Product Name Description Fe ee en Revac Hepaiits 8 Vaccine (DNA) Vial 0.5/1.0/50/10mL RevacdmeP RecombinantHepatiis 8 (DNA) vaccine (Thiomersal ree) | Vial/PFS o5/1omt INDIRAB® Purified Inactivated Rabies Vaccine (Vero cell} Vist o5/1omb TYPBAR™ Typhoid Vi Capsular Polysaccharide Vaccine Vials 0.5/2.5 mL JENVAC ‘Japanese Encephalls Vaccine, Inactivated (Adsorbed) Vial PFS 0.5/2.5 mL HNVAG® HIN] Pandemic fu Vaccine Vial O5/2.5mL BIO-HIBY Haemophilus influenzae Type b (PRP-TT Conjugate] Vial ‘yopriized Powder wih Divent 0.5m. TyobarTev™ Typhoid Vi Capsular Paysaccharde-TT conugate Vaccine | _ Vial PFS O5/2.5mL ROTAVAC Rojavius 1166 Vaccine (live atfenuated, Oral) Vial 0.5/2.5/5.0 mL BIOPOLIO*B1/3 Bivalent Polo Vaccine (tive) Vial (072.0 ‘Comvac 3 Dipthevia Tetanus and Perlusis (whole call Vaccine (adsorbed) | _ Vial PFS Omi ‘Com Vac 4-48" Diphiherio, Pertussis (w).Telanus, Hepat Val osm. (Diwe+Heo-8) Vaccine ‘Comvac © Bontril tana Repo FoemopnioTbenioe | ypps o5/25/5 mL REGEND &© FHumian Epidermal Growin Factor Gel (60 #6) Ube, TSS END 150 [Le Homan epidermal Growth Factor Gel (150 ual |__tube | _75ar159 SLVRGEN *- Human Epidermal Growth Factor, Siver Sulfadiazine & Tube 15/806 Chlothexidine Gluconale Cream seat Senceetsetr a corse are coer |eFuture Product Pipe Line_§ ———_____________________@ Product Name Pre Clinical Clinical Expected launch date Phare? Phase2— Pha Quarter / Year ko) ‘Chikungunya Vaccine TetanusToxoid (Meat free) Malaria PVR I THR 100 Lysostaphinfopical Sabin PV reas of interest for Collaboration © Development of novel Vaccines © Development of novel Therapeutics Contact Details o Name of contact person: Mr. Sal D. Prasad, President Phone +91 40 23480567 Adaress Bharat Biotech, Mobile ame Neiey) Fax +91 40 23480560, chy Hyderabad email prasadsd@bharatbiotech.com Stote figlongons, Website www.bharatbiotech.com Location India Postal code 500078 DEVELOPING COUNTRIES VACCINE MANUFACTURERS NETWORK devmnBiological E. Limited estapished Celebrating Life Every Day County India Overview of the company BiologicolE Lid (BE) is establshedin the year 1953in Hyderabad, India. Over the yeors, we have buill up a very significant share in the world of vaccine market, especially in the pediatric range. Our company is a major supplier to the National Immunization Programme {EPI programme} of the Goverment of India, UNICEF, Pan American Health Organisation and various Ministries of Health globally. BE envisages becoming a major world player in vaccine business by expanding the product range, market access, improving infrastructure through investments, increasing manufacturing and development capabilities and marketing agreements. BE achieved WHO Prequalification status for various vaccines viz, Tetanus, Pentavalent {DTP-HepB-Hib}, Japanese Encephalitis, OTP andTd. BEis the fist company in the world to get WHO prequalifcation for Jopanese Encephalitis vaccine, ‘As part of continuous efforis to develop new products for human use, BE is curently engaged in development and commercialzation of several recombinant, conjugate, bacterial & viral vaccines, BE has productive partnerships with several well respected and renowned institutions and Public Health Services across the world for joint development of new products fo full he ume! needs of India and other regions Product Name. Description Type. Presentation Via Abou | Pentavalent vaccine - liquid Comaerive | Diphner Telenuy, Pes, Heptis Band viaueis | 2 54 r0¢ore Haemophilus lype B conjugate vaccine (DTw?-Heps-Hib)| (Ha BET 7 Viel/ 1, 10 and 20 dose Adsorbed Tetanus Vaccine Ampoule Single dose DIwF TRIPVAC Diphtheria, Tetanus and Pertussis vaccine (adsorbed) Vial 1 8 10 dose 1d Berd Diphtheria and Tetanus vaccine (Td) (for Vial 1 & 10 dose edolescents & adult) ¥ 3meg /0.5 ml Jeev Jopanese Encephallis Vaccine, Inactivated (Stain Viat/Pes gmeg oem 3A\14-14-2 propagated on Vero cell ine) meg / 0.5 mi ‘OTHER VACCINES i 12,5 & dose | Hepatitis 8 2, bivac Hepaiils B vaccine (recombinan!) Vial Pediatric and 1810 dose Adult 7ARBEV eaiog ang Rubota Vaccine ive) (Aenuaied Vl 5M, 25MiRS mi BivAc oF lose ‘Adsorbed Diphiheria & Tetanus vaccine (for Pediahic) Vat 1 loa2oe Tehavelent_ DTP-Heps TRPVAC HB —_biphiheria, Tetanus, w-Pertussis, Hepatiis 8 (recombinant)| Viel 12,58 10 dose Viai is sslype b conjugate vaccine (iyophiized) | (combipack)| 5 & 10 doseFuture Product Pipe Line_§ ———_____________________@ Hexavalent - DIwP-PV-Hib-Hep8 TCV -Typhoid conjugate vaccine PCV - Pneumococcal Conjugate Vaccine ° ° © IPV- Inactivated Polio Vaccine ° ° HepA -Hepatilis A Vaccine Product Name Pre Clinical Phase? Clinical Phase2 Expected launch date Prose (Quarter / Year ao Areas of Interest for Collaboration © Vaccines ~ Bulk & Finished © Long term partnership arrangements Contact Details Name of contact person Address city State Postal code County DEVELOPING COUNTRIES VACCINE Ms. Kala Naidu, VP Intl Marketing Emcil id Ms. Divya Bilan, VP - SBD 623-H, Road No.35, Jubilee Hills Hyderabad Telephone Telengana Fox 500 033 Mobile India Web site MANUFACTURERS NETWORK kala.g@biologicale.com Inti@biologicale.com divya.bijwan@biologicale.com : #9140-71216260 / 71216000 » +914071216019 +91 9849557083, www.biologicale.com dcvmnPx Name of the company : PT Bio Farma (Persero) K y Head of nsitution _: M. Rahman Roestan CIOFALTNA exar00 1a90 Indonesia Indonesia Overview of the company Bio Farma focuses on research, development, production, marketing and distribution of biological and pharmaceutical products both nationally and globally, 8io Farma plays an active role in advancing the vaccine research and technology, conducting research on new vaccines in the effort of maintaining « sustainable vaccine supply in the country and the availabilly of vaccines to mee! the globalneeds of high quality and affordable vaccines, Supported by competence and experience for more than 128 years of learning, Bio Farma, a state-owned enterprise in Indonesia, manufacturing and distributing vaccines and one of a few WHO pre-qualified vaccine manufacturers, is here as part of he siruggle fo protect andincrease the qualily ofhumen ile, + Playing an important role fo establish a healthy nation in loparma ‘which ils existence would be maintained for generations to come. With our philosophy of being “Desicated to Bee improve Qually of Ute," we areready to devote ourefforts Innovation 9 Global Health Security, through Biolech for a better future provides solulions for global prospetily, For more information :www.biotarma.co.id for a Better Current Product Pipeline Produet Name Description Type Presentation Viey Armpoule 05/1.0/50/100m ‘Tetanus Toxold Vaccine Vial 50 mi/i0.0mi Uniject OS ml Biot Tetanus Toxold Vaccine “Ampoule osm or Diphtheria and Tetanus Vaccine Vial 50m 73 Tetanus and Diphtheria Vaccine [for adult) Vial 50m DIP. Diphtheria, Tetanus and whole cell Pertussis Vaccine Vial 5.0 m1 DIP-HB Tetravalent Combination Vaccine Vial 2.5 mi/5.0 ml 8 Hepatiis B Vaccine Unject osm 1.0 ml for adult) TOPV, OPV | _Monovalent, bivalenl Polio Vaccine Vial 20m Measles Measles Vaccine Vial 10 doses/20 doses BCG Tuberculass Vaccine “Ampoule 20 doses Flubio ‘Seasonal ily Vaccine Vial OS m/2.5 mi DIP-HB-Hib | Dishtheria, Tetanus, Whole-cell Pertussis, Hep-B and Vial 0.5 mi/2.5 mV5.0 mi (Penlabio) | Haemophilus influenzae type bFuture Product Pipe Line§ ——_____________________@ © Sobin-PV [sIPV} © Rotavius Vaccine © Fly Vaccine (Pandemic) (© Measles Rubella Vaccine (© Typhoid Conjugate Vaccine Product Name Pre Clinical Clinical Expected launch date Phase? Phase2 Phase 3 Quarter / Year Sobin-PY (SIPV) Rofavins Vaccine: Fiu Vaccine [Pandemic] Measles Rubella Vaceine Typhoid Conjugate Vaccine oo Areas of Interest for Collaboration © Capacity Building © QMS Training © Research © Product Development & Process Innovation © Marketing & Distribution Contact Details e Name of contact person: Bambang Heriyanto Phone +62 22.203 3755 Address Jalan Pasteur No. 28 Mobile city Bandung Fox +62 22.204 1306 State West Java email mall@biofarma.co.id Location Indonesia Website www biofarma.co.id Postal code 40161 DEVELOPING COUNTRIES VACCINE MANUFACTURERS NETWORK devmneach Name of the company :Blo-Manguinhos - immunobiologicals Technology Insitute @ Bio-Manguinhos The Oswaldo Cruz Foundation = Minishy of Health Head ofinstitution —: Maurfclo Zuma roca Established ‘May 04, 1976 Fandagbe Onwoldo Cruz County Brazil Overview of the company Bio-Manguinos was foundedin 1976 to strengthen vaccine manufacturing capacity to meet publc health demands, as defined by the Ministry of Health (MoH) Nationalimmunization Program (PN). Since then, the Institute has layed © prominent role in government health. programs, investing in. innovation, technological development and manufacturing of vaccines, in vitro diagnostics and bioptherapeutics. Our portfolio is made of 31 products, which are supplied primarly lo the Unified HeattnSysiem (SUS) To master advanced praduction processes ond state-otthe-art technologies, Blo- Manguinhos besides in house R&D, invests ako in partnerships and technology transfer ‘agreementswilh nationalandinterationalinstitutions. Bio-Manguinhos s also a member of he Executive Group of Health Induslial Complex (Gee's) which rings together government authotties, representatives of the national industry, associations and teaching andresearch insilutions, as wellas funding agencies, Asamemiber ef Gees, it contributes to the formulation of health public policies. The changes go further and the Insitute is constantly growing and strenthening ils technological copatilles. The Industiol Health Biotechnology Complex (CIB), in Santa Cruz, Rio de Janeito; and the Vaccines Plant Based Technology Center. in Eusebio, Ceare are the two newes! sites under construction. The bulling of new facies willalow the expansion of productive capacity. Current Product Pipeline. ——________________________» Frodvct Name Description ee Fresentation Vascher ore + Hoemophiustnfuenea ype Scdoses/vial 25m FE TSE MSpRE MvENTS VES Tones cores —| US oRIZTAT mg Hearies Mumps and Robe 10 doses/val 507m aM ‘Measies- Mumps. Rubela ond Vaneola 1 dose/via Om ory rat Polomvehis Tasos ue 25m BV. Tnactivated PolenvaE 10 doses/vial 30m Rotana Rovaws vaccine Tose via 207m Deve cca 10 - valent Preumococealvaccne Tas Om Royaccharkie Poiysaccharicle Meningils AC vaccin 10 doses/val 1m Yellow Fever Yellow Fovervaccne: Eldend Siders [05 Oana 750 IVD Reagents NATHIV/NGV IA Walecvie Biology NAT Asay HVGVINEY | 96 reactions7ai 206 (ka, Dengue and Molecular Biology Assay for Zko, Dena v0 Ghiednauinve) Sha Ghlongurga feactions Tmunablet OTN Rapid Tost = Imunablot DPF EN TS eae DPP* HIV Rapid Test “OP PTH Droste Sratig oe Shale sised DE Syphie Rapial Test - OPP Sype eae i PP” Syphilis DUO Rapid Test DFP" Syphils (Non Irgponer 20 testskit 7 DPF HIV /Syphis Combo | Raped Lesh; DPR HIV / Sypris Combo. lests/kit - DPF Canine Leshmarioss | Rapid Tes! - DPP* Canine Leshmaniass Desire = DEP Leptospioss Rapid Test = DPM Leptoapioss eat : Derr Rapid Test = OPP Zk 20 esis = DPF chignaunva Rapid Tes! = DPF" Chianaunya 20 fess = Chagas Ditease IFA Tmmmunotlverescanee - Chagas DReare 600 tes = Conine loshmaniars ELSA | SLBA ~ Canine Leshmariass Sea tora Human Leithmoniass FA | Immunolluorescence - Human Leshmaniass| 400 tess = Helm Test Kato Kaiz— Helm Tor To Tessar PS: DPP* = Dual Path Platform. Biopharmaceuticals ‘aan osaroo inferferon alpha 76 Tnfetreron alpha 7b recombinant Tend mal ‘Omi Eryihropote Eryihropoletin recombinant 75607 0007 1,000 UIT Omi Altaigiceroz Talgueerese ofa 200 Uf wal Som Tein Irfan ao mahal DOme Belainterfaron ba Betainferforon To recombinant Hand meg sehlesayinges | OSTFuture Product Pipe Line_§ ———_____________________@ © Conjugate Meningitis ¢ Vaccine © Coriugated Mutivalent Meningitis Vaccine © Dengue tetravolent vaccine inactivated) © tka vaccine © Yellow fever vaccine improvement fatienuated) © Yellow fever vaccine [inactivated} © Yellow fever vaccine [plant-based vaccine) © Measles and Rubella vaccine © Peginterferon Alpha 26 © Humanized monocional antibody Ani-MRSA, (© ex NAT Assay HIV/HBV/HCV (© NAT Assay HIV/HBV/HCY + new targets (ex: malaria} © Liquid Microarray Product Name Pre Clinical Clinical Expected launch date Phase? Phase? Phase 3 ‘Quarter / Year Bacterial vaccines F F F 7 Viol vaccines 4 1 i Biopharmaceulicals 1 1 Vo reagents 4 1 : oe Areas of interest for Collaboration (© Prokaryatic expression © Eukaryotic expression © Conjugation © Plant based Contact Details ° Name of contact person: Mrs. Denise Maria Lobo Criv Phone: +8521 3882-9329 Address Avenida Brasil, 4365 -Manguinhos Mobile: +5521 99395-0839 cay Rio de Janeiro Fox 5 #8521 3882-7175 State Rio de Janeiro email dlobo@bio.fiocruz.br Location Brazil Website: www.blo.flecruzbr Postal code. 21040-360 DEVELOPING COUNTRIES VACCINE MANUFACTURERS NETWORK devmnioNie SE ea Country Thaitand Overview of the company BioNet-Asia Is « Biotech company focused on the development and production of the next generation of innovative vaccines. BioNet aims to provide arapid accesso Ife-saving vaccinesto the neediest on all continents, BioNet is the only manufacturer of recombinant acellular Pertussis vaccines produced by using a patented recombinant DNA technology. These coniain a genetically-inactivated Pertussis Toxin (PTgen} which induces higher anii-PTimmune response as demonstrated in several clinical trials, Two PIgen-containing vaccines are alteady available in Thailand: Pertagen®, a monovalent acellular Pertussis (aP} vaccine and Boostagen®, a Tetonus-diphtheria-ocelivlar Perlusss (Td?) combination vaccine which are used for booster immunization in adolescents and ‘adults including pregnant women, With @ global market reach and network expertise, BioNet has also been supporting vaccine manufactures in their rapid expansion into international and emerging markets. BioNet is offering access to voccines and technologies through global partnerships that have led to ‘the supply of bilions of doses of vaccines worldwide. For additional information, please visit www.bionet- asia.com Current Product Pipeline, ————_____________ lg Product Name Description Type Presentation Viai/Ampoule 05/10/50 / 100 m1 Pertager® Recombinant acellular pertussis (aP) Pes 05 mi Boostagen’ ‘Adult TdaP vaccine (letanus-Diphiheria- prs osm Recombinant Pertussis vaccine] Hib" Haemophilis influenzae type b vaccine Bulk *manufacturing parnershipFuture Product Pipe Line_§ ———_____________________@ © Pediatric combinations © Dengue vaccine © Tika vaccine ProductName Pas! Pre Clinical Clinical Expected launch date ‘RD phove Phase! Phaie2 == Phase 3 (Quarter / Year Pediatrie combinations Dengue vaccine Tko vaccine a Areas of Interest for Collaboration © Marketing and Distribution of vaccines © Vaccine joint development and R&D collaborations © Technology transter for Hib, HBV, HPV, Rabies © In-and oubticensing opportunities Contact Details o Name of contact person: Dr. Pham Hong Thal Phone +66 35.246924 Address Hi-Tech industrial Estate, 81 Moo 1, Mobile Boan Lane, Bang Pa-in rol Pere miree city Ayutthaya email Info@bionet-asia.com State ‘Ayutthaya Website: www.bionet-asia.com Location Thailand Postal code 13160 DEVELOPING COUNTRIES VACCINE MANUFACTURERS NETWORK devmnName of the company : BravoVax Co,, lid Bravo’: Head of Institution _: Dr. Ke WU, Chief Executive Officer ax Established 2012 Country PRChina eS Overview of the company Estoblshed in year 2012, BravoVax is c private pharmaceutical company specialized in development, production ond commercialization of human vaccines. Is stuated at Wuhan, alarge modem city in central China, BravoVaxis committed to supply sofe, effective and affordable vaccines to protect the vast populationin the developing workd trom variousinfectiousiinesses. ‘The current product pipeline includes vaccines against bacterial and viral diseases. The fist vaccine product of the company, @ fetravalent attenuated oral rotavinus vaccine, was sublicensed from USA in 2014 and is expecting to enter the clinical tial phase in 2017, BravoVax currently possess a R&D and pilot production facilly with fourvaccine technology platforms and wo pilot production lines. The company has established the quality system os per WHO cGMP requirement, In addilion, © state-of-the-art industrickscale facilty is being planned with a capacity of 100 millon doses per year, which will not only meet the domestic needs, but ‘also to enable the company to provide vaccine supply to the large populationsin developing counties. BravoVax has established active partnership with various renowned academic insllutions worldwide. The company strategy is to collaborate with the global health community on the development of vaccines to address unmet heatthcareneeds, Current Product Pipeline. ——____________________»® Product Name Description Type Presentation Vial/ Ampovle 05/1.0/50/100 mtFuture Product Pipe Line_§ ———_____________________@ © Rotavirus Vaccine © Pneumococcal Vaccine © Respiratory Syncytial Virus Vaccine © ka Virus Vaccine Product Name Pre Clinical Clinical Expected launch date Phase? Phase2—— Phase 2 (Quarter / Year Rotavius Vaceine 2020 Pheumococeal Vaccine 2021 Respiratory Syncytial Vius Vaccine 2023) Tka Vins Vacene 2025 oA Areas of Interest for Collaboration © Vaccines targeting diseases responsible for high rates of mortality and morbidity in developing counties © Therapeutic biologicals that targeting diseases with high social and economic burdens in both established ‘and emerging markets (© Technologies improving the vaccine accessibility and affordabilty in developing world settings Contact Details Nome of contact person ‘Ms Xiaoshu ZHANG Phone Address BravoVax Building, 858 Gaoxin Avenue Mobile BioPark, Donghu Dev.zone rox city Wuhan email State Hubei Province Weball Location PR. China Postal code: 430075 DEVELOPING COUNTRIES VACCINE MANUFACTURERS NETWORK +86 27 87988585 +86 13916244379 +86 27 87988595 xigoshu.zhang@bravovox.com www.bravovax.comName of the company : CPL BIOLOGICALS PRIVATE LIMITED CPL ¢« Head of isitution —: Mr tin Tomar, President BIOLOGICALS eraines ss cS Overview of the company Based in Ahmedabad, India, CPL Biologicals Pvt. LId. is a joint-venture biotechnology company established in 2009 by Novavaxine., USA and Cadila Pharmaceuticals Limited, one of India’s larges| privalely held pharmaceutical companies. CPL Biologicals has a thee pronged approach to providing novel solutions for global healthcare - vaccines, biologics and diagnostics, with integrated capabilties from early stage research and development to clinical and commercial manufacturing along with dedicated sales and marketing teams. CPL Biologicals has established state-o-he-orf R&D and manufacturing facities in Dhoka, Gujarat {India}, which currently has the capabilty of producing up to 25 milion doses every year. CPL Biologicak: aims to be a leasing provider of high quality novel vaccines, biologics and diagnostics through world-class research and innovations combined with cost effective and cfficiont manufacturing to address current and. fulure globalhealth challenges, Current Product Pipeline Product Name Description. Type Presentation Mia Ampoule 05/1.0/50/100 mi Cadily (Pandemic VL? based HIN! Vaccine Viol O.smi Influenza Vaccine} CadifuS (Seasonal Influenza Vaccine} VLP based Trivalent Influenza Vaccine Viel 05 miFuture Product Pipe Line_§ ———_____________________@ © Rabies Vaccine © Quadrvalent Influenza Vaccine © Varicella Zoster Virus Vaccine © Pancreatic Cancer Vaccine Product Name Pre Clinical Clinical Expected launch date Phase! Phase? Phase 3 ‘Quarter / Year Rabies 3 dose Vaccine (2/2019 Pancreatic Cancer Vaccine Rabies single dose Vaccine Varicella Zoster Virus Vaccine |e] __ Are ass of Interest for Collaboration Development and adoption of new products and technologies through Partnerships Vaccines for commercialzation by CPL Biologicals ° © Recombinant proteins and Monoclonal antibodies for therapeutic use ° ° In icensing fout icensing Contact Details Nome of contact person Adress ciy stale Location Postal code: DEVELOPING COUNTRIES VACCINE M. Alin Tomar 1389 Trasad Road, Dholka: Ahmedabad Gujarat India 382225 Phone Mobile Fax ‘email Website MANUFACTURERS NETWORK 491 2714 221481 82/83/84 Ext. 248 +91 8130811877 +91 2714 221048 atin tomarsepibio.com www.cplbio.com dcvmnName of the company: Center for Research and production of Vaccine and Biological (POLYVAC) Head of Insltution Dr. Nguyen Dang Hien, Director Established 5 24 January 1994 Location Hanoi, Vietnam POLYVAC Overview of the company Center for Research and Production of Vaccines and Biologicals {POLYVAC) was estabished in 1994 by the Ministry of Health of Vieinam with the task of carying out experimental research, application of new technologies for production of Vaccine and biological produels From tne end of 1962, the Division of Sabin’s Oral Polio Vaccine Production of the NIHE was able to produce 2 milion doses of oral polie vaccine for children of North Vietnarn. With the great efforts ofall professionals and staf, with unity ond self sufficiency spt in ‘order to full he assigned tasks and duties, the ‘quantity of vaccine produced by the Center has increased every year up to 40 milion doses, meeting the national vaccination demand for eventual recognition in 2000 by WHO that Vieinam was pote tree. Besides the production of OPV, Center ao conducts research and produces olher vaccines such as: IPV, Rotavirus vaccines and Measles vaccines meets GMP/WHO with technology tronsferted by Japan. At present, Measies vaccine has beenlicensed, Since 2010, Vieinam wil stop importing measles vaccine, nile being active in preventing and controling measies as recommended by WHO. The Rotavius vaccine ishas been licensed also from 2012. Current Product Pipeline. ——_______________________@® Product Name Description Type Presentation Vioiyampoule ——08/1.0/50/ 10.0 mi loral polio vaccine Tetravalent, ve, attenuated oral vaccine Vial ‘2mi/20 doses/vial Measles Vaccine Froeze-dried, ve attenuated vaccine. AIK-C Strain Vial Smi/10 doses/vial Rotavirus vaccine| Live attenuated oral vaccine. Human strain G1P(B] Vial 2mi/ dose/vialFuture Prodyet Pipe Lie | —$@$-@€£$§#942 iMJUWNNW_____________® ° ° ° ° Rubella Measles Rubella combine vaccine Inactivated Polio vaccine borv Product Name. Pre Clinical Clinical Expected launch date Phase? Phase2-— Phases Quarler / Year borv 4/2015 MR 24/2016 ov 3/2016 oe Areas of Interest for Collaboration Contact Details e Name of contact person : Dr. Nguyen Dang Hien, Director ‘Adgtess : 135 Le Due Sheet Phone: +84 438211782 Mobile : +84 913236890 City : Hanol State Fax: +84 438213203, Location : Vietnam, ‘email : danghien@fpt.vn Postal code: 10000 Website: polyvac.com.vn DEVELOPING COUNTRIES VACCINE MANUFACTURERS NETWORK devmnName of the company : Changchun BCHT Biotechnology Co Head of institution _: Dr. Kong Wel Established ‘March, 2004 BCHT Country PRChina Overview of the company Changchun BCHT Biotechnology Co., established in 2004 and located in Changchun, is a biophormaceutical enterprise engagingin research, development, production and marketing of vaccines, biologics and peptide arugs. BCHT has welLestablshed innovative platform by the most talented researchers and with the state-of-the-art facility. The management team consists of the members with strong international background and extensive experience in China in biopharmaceutical industry. BCHT owns among the most advanced R&D laboratories and pilot plants for vaccines and peptide drugs n China. Currently, there are two vaccines, varicella and rabies, in the morket and many products, such as HIV vaccine and LAIV vaccine, in its developing pipeline at the different stages. The manufacturing plant, production process and quality assessment and control are fully with the compliance of GMP requirements and some products aim at receiving WHO prequaliication Inthe near future. BCHT hos established @ wide cooperation with Intemational partners for technology promotion ‘and product marketing. For example, LAIY isthe project collaborated with WHO. The companys products have received the certificate or are in the process of registration for the permit of market access in many counties. BCHT is to strategically explore the interational market ‘and business opportunity with the partners. Current Product Pipeline, ————_____________ lg Product Name Description Type Presentation Viai/Ampoule 05/10/50 /100m Varicella Vaccine. ve | Gelatin-ree, valaity for 36 months lyophilized, Vial ‘oSmiviol (Oka sain Rabies Vaccine (vero | Produced with microcarier bioreactor with Vial Lomivial Coll for Human Use high potency not less than 2.510Future Product Pipe Line_§ ———_____________________@ Tester Vaccine HPV Vaceine AIDS Vaccine RSV Vaccine VIV Vaccine Cancer Veecine V7 Vaccine: e0000000 Product Name Acellvar D1P Vaccine: live Attenuated influenza Vaccine Pre Clinical Clinical Phase? Phase 2 Expected launch date Prose Quarter / Year ‘Acelver DIP Vaccine: Live Attenvated Influenza Vaccine Tester Vaccine HPV Vaccine ‘ADDS Vaccine RSV Vaccine Viv Vaccine B71 Vaccine oe#—___T_.WTJT a Areas of Interest for Collaboration Voceines Bologies e000 Export Contact Details Peptide and chemical dugs Name of contact person Address city Stale Wu Jinchang Phone 1260 Huoju Road, Changchun High-Tech Mobile Tone, Changchun, Jitin 130012, P.R. China Fox Changchun email Jilin Province Website P.R. China 130012 DEVELOPING COUNTRIES VACCINE MANUFACTURERS NETWORK +486 431 87078891 +86 15084068371 +86 431 05195516 info@bchtpharm.com hitps://www.behipharm.comName of the company : China National SE EVEPZE NM) te2sotrsvvton ctromin Yan chakmen CNBG jotec Group Company Li mee Established asg County PRChina Overview of the company (CNBG has been dedicated in the field of healthcare since 1919. I's the largest state-owned biopharmaceutical company in China in terms of product portfolio, production capacity and company scope. It runs 6 business sectors including human vaccines, blood products, animalheatth, medicalaesthetics, Giognestics and antibody. CNBG con produce 50 kinds of human vaccines against 33 Infectious diseases. The annual capacity could reach up to 700M doses. It is the major supplier fo Chinese EPI program. II is also the largest blood producer in China, with more than 1000 tons of plasma collection capabilly tis the only botulinum toxin producerin Chine and the fist Chinese company pre-qualified by WHO. CNBG currently owns 1 innovative vaccine RED center, 6 human vaccine manufacture sites, 2 animal vaccine manufacture sites, 1 diagnostic company and 1 public Isted company (TiantanBio) for plasma derived products. CNBG has more than 10,000 employees. The total asset has, reached 3.6 8n USD in 2017 while the total revenue hos reached 1.38nUSD, Current Product Pipeline ———______________ioo Product Name Description Tvpe Presentation viayampoule 05/10/50/ 10001 Hepat vaccine (year Ampouie 0200 BCG vaccine forinradermaliecton “Ampoule | 0a5ma/sdoses OPV Wve ailenvated human cine call via Ti 2odsoshc Shoriora Dither Tetanus ond Acer Pertusis combines (OTR Aakaroea] AmoupleVel om Tisai, Muri and Robes Combined vaccine, Uve TeaisThR Var oan REY Jopanete Encephalitis Vaccine lve Val asm Menatngkone Group A*C Meningococcal Poksacchande vacche ‘Ampovle | Wapdowe s0vaTars Group A MeringbencealPalnaccharkle vaechne Tompoule ia en aves Live alienwated Hepattis A vaccine Val in Spit hfvenza vive voocine TeaiearyechT] 0a. oF Tao 7 Valen] Pnsuriacaccol PoNGaCoTaIge WOES Val a Toutewet tive Rotavins Vacene fro Val Osri Reorbel Taomophisiivensa ype De Val aan Shengdou Freore-died ive alenwated Varcela vaccine var Tani Woahenganniig | Rabies Vaccine for oman ume [VERO cel Val Tsao Yelbw Faver Vaccine, tive Val O5ni Typhoid W Fotaccharde voce apa Tazo Tertabao Tek Bore Eheepholis Paied Voce ampaule i Taman Abn Val ese 06258 Fuman inmoneglobuln [pa invavensus nection Var 125.255 Human Hepat 8/letanus/ Rabies mmrunoglobuin vo | SER ZT aT Taio Botuinom Toa AToriection Val Sow. 100 Yl Evi vaccine val OSI SPV vaccine VialFuture Prodyet Pipe Lie —§ —$@$@ £-£€£@§£-$§jIj}N7}Y]WNNN eee inp Clinical Expected launch date eer Pre Clinical ried rate rhaie2_—— Phased Quarter / Year Boling Stain Varicola Lve Atenucted Vacene Tivalent Reawortant Rotavius Vaccine Typhoid Vi Conjugate Voccine Recombinant Blood coagulant factor Vi Tekavolent ty Hexavalent Ralavis Vaccine Tevalen! Preumacoccal Conjugate Vaccine ie Weel P TVecies Mumps, pba a Vacate Comared (Vases tia Wi Therapeutic Hep | ee tale We Novell vache etre of interest for Collaboration © Combined Vaccine © Tumor vaccine © Inmuno-eneslogy © Cattherapy © Gene herany © Novel aciuvant, vector © New target” MOA © New cot substrate © Formutaion © oveseas enicatresearen © Emergency response patforn (© Researcher traning ond exchange Contact Details ° Name of contact person: Ms.LIMeng/Ms. QU Liang/Mr.XUYe Phone: +8610 84663783, 84663787/ 84gs9183 address 15-14th Floor, Fortune Tower B, No. 4 Mobile +0613 13693264898/ Huixin East street, Chaoyang Dishict see a2 88260 tty Beling Fox +86 1084663322 Site Belling email limeng3@sinopharm.com, Location pR.China quliangésinopharm.com, xuye3@sinopharm.com Postal code 100029 Website www.enbg.com.cn DEVELOPING COUNTRIES VACCINE MANUFACTURERS NETWORK devmnName of the company : Chongqing Zhifei Biological Products Co., Ltd @ zesw moe Country P.R. Ching Overview of the company Chongaing Zhife Biological Products Co, Lid was foundedin 1995, headquartered in Chongaing. Zhifelis a hitech biological enterprise, with the registered capital of 1.6 billon RMB, a total asset of 4.8 billon RMB and more than 2000 employees up lo now. Zhifel is focus on technological innovation and market access of human vaccine and bio-products in R&D, manufacturing, sales. It passesses 4 wholly-owned subsidiaries, there are one plant ste and one trading company located in Bejing, another plant iesin Hefei, one more plantin Chongaing, Inits state-of-the-art vaccine plant in China, Zhifelis aso building a unique expertise in 18, protein conjugation, cell-culture and vaccine formulation. The company has developed a broad pipeline with 20 products in R&D and clinical stages, including vaccines and recombinant proteins conjugate vaccines. The company has sold more 2 millon vil meringits vaccine which is now commercialzed in Asa market. Zhifel has recentWy fled 9 patents y application for its new Vaccines which are now Uy feebotes Im chica wal Teh uauely Postioned as @ major partner in technology Ny onterondmatetorcen ebay ‘Current Product Pipeline Product Name Description Type Presentation Viai/Ampoule 05/10/50 /100m Vacces Mycobacterium Vaccae for injection Viel 22.50uq/vial Group ACYW135 Meningococcal Men ACYWISS polysaccharide vaccine Viel O51 Men AC ps Group AC Meningococcal poiacchoride Viet smi Men AC con] Group AC Meningococcal conjugate Vial osm Meningococcal Group AC ond Men ACH Haemophilus Type b conjugate vaccine Viel 0.5m ib Haemophilus Type b conjugate vaccine Viet osmFuture Product Pipe Line_§ ———_____________________@ © Typhoid Conjugate Vaccine ‘© Pneumococcal Conjugate Vaccine © Meningococcal Conjugate Vaccine Product Name Clinical hose 1 Clinical Phare 2 Expected launch date Phare ‘Quarter / Year ‘MenACYW135 Con] Shigella flexneri 2a and Sonnei Con} PPSV23 Hl treeze-ctied ecvis Ticomponent DTaP. EV7) Inactivated T+Coxsackievirus ANS Rotavius inactivated ‘Quadrivalent Fly Sol Rabies (MRC-5) Rabies|Vero cel) Mycobacterium. vaceae vaccine [for TS) T6-CPFIO Allergen (EC test reagent) Recombinant TB vaccine (AEC/BCO2) acc BCG PPD Hep8 (Hansenula polymorpha) Norovirus (Pichia pastoris ka virus vaccine oA Areas of Interest for Collaboration ‘echnology transfer and co-develooment R&D and tech innovation Long term & stability marketing and distribution ° ° © Inlemational cooperation of vaccine ° ° B products cooperation © Finish or semefinished products Contact Details Name of contact person: Mr. Tian Jia 25/F, No.7 Jinyuan Road, Address Jiangbei Distict city Chongaing State Chongaing Location PR China, Postal code. 137894 DEVELOPING COUNTRIES VACCINE MANUFACTURERS Phone. Mobile Fox email Website NETWORK +86 10 67872383, +86 15210159969 +86 10 67872383, flanjia@zhifelshengwu.com www.zhifeishengwu.com/ ‘aspx/english dcvmnName of the company : EuBiologies Co., Ltd . . Head of rstuion Dr Yeong-Ok Balk, CEO eubiologics . bobbed och 102018 county epubte of Korea ae overview of the company EuBiologics Co.., Ltd. is @ Korean biopharmaceutical company providing contract research and manufacturing services to domestic and international clients, in addition fo building a portfolio of vaccines designed to improve global public health The company was established in March 2010 with the objective of becoming a preferred strategic partner providing solutions for the development and manufacturing of biopharmaceutical products and went public an the KOSDAG in Jan 2017. EuBiologics’s facilties are designed to manufacture a variety of mammalian cell and microbe-derived, protein-based therapeutics and antibodies. It provides customized services for various stages of product development, including cell line development, "Good Manufacturing Practice" (GMP) production, validation and regulatory support. The company has also licensed the manufacturing technology necessary to produce an oral cholera vaccine trom the Intemational Vaccine Institute. n parallel with the development ofits oral cholera vaccine product (“Euvichol” ond “Euvichol Plus"), EuBiologics is pursuing @ number of other vaccines against diseases such as typhoid fever, pneumonia and. meningitis i ab aeppeamandl c passes inane ania The company’s administrative headquarters i in Seouland its manufacturing facillies are located in abiotechnology cluster in Chuncheon, Korea, For additional information about the company, please visit htlo://wrwweubiologies.com/ENGY. Current Product Pipeline, ————_____________ lg Product Name Description Type Presentation Viai/Ampoule 05/10/50 /100m Euvicho? (Oral Cholera Vaccine Vial 15m EuvicnolPlus” (Oral Cholera Vaccine Plastic Tube 15 miFuture Product Pipe Line_§ ———_____________________@ © Typhoid Conjugate Vaccine © Pneumococcal Conjugate Vaccine © Meningococcal Conjugate Vaccine Product Name Pre Clinical Clinical Expected launch date Proves ‘Quarter / Year Typhoid Conjugate Vaccine Pheumecoccal Conjugate Vaccine Meningococcal Conjugate Vaccine oe Areas of Interest for Collaboration Development of bacterial conjugate vaccines Development of combo vaccines e000 Virus Like Particle (VLP} based vaccine development New adjuvant development, Menophosphory! Liquid A produced from E.Coli (EcML} Contact Details Nome of contact person Rachel Pare Adress 4F Bomal-A-Chim 8/0, Mabang-t08, Seocho-gu oily » Seoul Stole Location Republic of Korea Postal code: 137894 Phone Mobile Fox email Website DEVELOPING COUNTRIES VACCINE MANUFACTURERS NETWORK 482.2572 6675 +482 1042628187 40225746678 rachel park@eubiologics.com www.eubiologics.comName of the company : Finlay Institute FINLAY £& Hoag otinsuion _: Bt Coneepeién Campa Huerge resent / Gonerl Director Established 27th Ave No. 19805, La Coronela La Lisa, Habana City Location cuba Overview of the company he FINLAY INSTITUTE, founded in 1991, is a scientilic organization, dedicated lo research, development, production ‘ond commercialzation of human vaccines, intemationally recognized in this Feld. This institution is a world leaderin the field of meningococcal vaccine and other classic vaccines includedin the Extended Immunization Program (EIP). VA-MENGOC- 808, created and produced by the Finlay institute was the fist effective vaccine against serogroup Bmeningococeus, he almost 1000 members of Finloy's staff constitute the largest capital of Finlay Institute and they have been recognized for their experience in the field of vaccines, more than 60% of them have high technical and professional qualification in the field of vaccine research, development, production ‘and quality control. Many of them have more than 20 years of experience in these specialties, which guarantees the preparation and conlinuily of the projects ‘with the inclusion of new talents graduated, from the universities. The facilties engaged in the production of vaccines and active pharmaceutical ingredients were designed, built, equipped and they are operated according fo cGMP. Some products manufactured in these facillieshave been prequalified by WHO, Current Product Pipeline Product Name Description Type entation WavAmpeule 05/10/50 / 100m VAMENGOC-8C® Meningococcal BC vaccine Vial 05/25/50 mi Vax MEN-AC® ‘AC Meningococcal polysaccharide vaccine Vial 50m VORMEN: ACW Meningococcal ACW.,, vaccine Vial 50m vorSPRALE Tivalent leptospirosis vaccine Vial 0.5/5.0 vax tyvie Vi polysaccharide typhoid va Vial 05/5.0/10.0 mi vor E18 Tetanus vaccine Vial 05/5.0/10.0 mi VADIFETS Diphtheria-Telanus vaccine for ehisten Vial 0.5/5.0/10.0 mi divox® Diphihero-Tetanus vaccine fer adulls Vial 0.5/5.0/1000 mi DTP. vax Diphtheria: Tetanus wPeruss vaccine Vial 0.5/6.0/10.0 miFuture Product Pipe Line§ ————________________@ © Cholera vaccine (atlenvated! (© Plain ACYW),, meningococcal vaccine [porcine components tree) (© AW, OMV vaccine (9 Plain polysaccharide Vi Vaccine [porcine components tree) (9 Ploin ACYW/.. X meningococcal vaccine Product Name Pre Clinical hate 1 © AW..X OMY vaccine © Conjugated Vi polysaccharide vaccines (© Conjugated Meningococcel ACYW,,.X vaccine ‘© Once BCS Clinical Expected launch date Phase? Phase 3 ‘Quarter / Year [Cholera vaccine (attenuated) Ph ACY, erngocoea vache ccorpnenel// ZL. (AW, OMV vaccine an poyrocchande Vivaccie pore compares ee) Piain ACYW,,, X meningococcal vaccine AW..K OMY vaccine YZ or / Gengcted Nenrenconea ACTH, Xvacarelf onc W a . Areas of Interest for Collaboration © Cooperated manufacturing © Vaccine technologycal transfer © Bacterial vaccines development based on outer membrane vesicles and based on capsule polysaccharides © Application of novel adjuvants based on serogroup B Neisseria meningiligis outer membrane vesicles and proteoliposome-detived cochleate structure for vaccine development Contact Details Name of contact person : Dr. Concepeién Campa Huergo Address : Ave 27 No, 19805, La Coronela, Lo Usa, City : Havana Slate Location cuba Postal code: 11600 DEVELOPING COUNTRIES VACCINE MANUFACTURERS NETWORK Phone : + §3 7 208 6086 +53 7 208 0975 Mobile : + $35 285 0016 Fax: + 63 7 208 6075 ccampaGfinlay.edu.cu Website: www.inlay.edu.cu dcvmnName of the company : Fundagéo Ataulpho de Paiva uM nt Established 1900 je teenicn inna ty Bratt Overview of the company Fundagéio Ataulpho de Paiva (FAP) isa nonprofit, philanthropic private insfitution founded in 1900 and was named Braziian League Against Tuberculosis, FAP has been promoting scientific advances and producing 8CG Moreau Rio de Janeiro vaccine strain since 1930. FAP aclivlies are based on production, research and social assistance programs. The Braziian Ministry of Health has given competence to the Fundagae for manufacturing, importing, exporting, stocking, distribution and repackaging of drugs, raw materials and dietary products BCG Moreau Rio de Janeiro is one of the four BCG vaccines considered as Reference Reagent by the World Health Organization (WHO). In 2012 the Moreaustrain was studied by 16 laboratories from 13countries cerlifledby WHO. The high immunogenicity andlow side effects of the Brazilian vaccine have been ‘demonstrated. The genome sequence and proteome analysis of the strain were abo studied, 2006 IMUNO BCG waslaunchedin Brazil. It was developed from The BCG Moreau Rio de Janeiro strain, ts used for the treatment of superficial bladder cancer. Currently, FAP has two plants. One ino de Janeiro city and otherin Duque de Caxios district. Bothin Rio de Janeiro Stat Current Product Pipeline Product Name Description Type Presentation Vioiyampoule ——08/1.0/50/ 10.0 mi ace, BCG Vaccine ampoule | Img/10 doses IMUNO 8CG IMUNO Therapy for superficial bladder cancer ampoule | 40mg/Intrabladder